Non-Alcoholic Fatty Liver Disease (NAFLD) Drugs Market Trends 2021 | Segmentation, Outlook, Industry Report to 2027

The Non-Alcoholic Fatty Liver Disease (NAFLD) Drugs Market size is expected to grow at an annual average of 57% during 2021-2027. Nonalcoholic steatohepatitis is a form of liver disease that occurs in people who consume little or no alcohol. Nonalcoholic steatohepatitis (NASH) is one of the most common liver diseases, often called silent liver disease. A key characteristic of NASH is the accumulation of fat in the liver along with inflammation.

The following segmentation are covered in this report:

By Drug Type  

• Vitamin E & Pioglitazone
• Ocaliva
• Elafibranor
• Selonsertib & Cenicriviroc

By Sales Channel

• Hospital Pharmacy
• Online Provider
• Retail Pharmacy  

 Company Profile

• Pfizer Inc. (Pfizer)
• Roche Holding AG (Roche)
• Takeda Pharmaceutical Company Limited
• Intercept Pharmaceuticals, Inc.
• AstraZeneca PLC
• Novartis AG
• Merck & Co., Inc.
• AbbVie Inc. (AbbVie)
• Gilead Sciences, Inc.
• Genfit Biotechnology

Scope of the report

The research study analyses the Non-Alcoholic Fatty Liver Disease (NAFLD) Drugs Market industry from 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions, considering multiple aspects some of which are listed below as:

Recent developments

• Market overview and growth analysis
• Import and export overview
• Volume analysis
• Current market trends and future outlook
• Market opportunistic and attractive investment segment

Geographic coverage

• North america market size and/or volume
• Latin america market size and/or volume
• Europe market size and/or volume
• Asia-pacific market size and/or volume
• Rest of the world market size and/or volume

Key Questions Answered by Non-Alcoholic Fatty Liver Disease (NAFLD) Drugs Market Report

• What was the Non-Alcoholic Fatty Liver Disease (NAFLD) Drugs Market size in 2019 and 2020; what are the estimated growth trends and market forecast (2021-2027)
• What will be the CAGR of Market during the forecast period (2021-2027)?
• Which segments (product type/applications/end-user) were most attractive for investments in 2021? How these segments are expected to grow during the forecast period (2021-2027).
• Which manufacturer/vendor/players in the Non-Alcoholic Fatty Liver Disease (NAFLD) Drugs Market was the market leader in 2020?
• Overview on the existing product portfolio, products in the pipeline, and strategic initiatives taken by key vendors in the market.